Protocol Ledger

NCT04740918 · Phase III · TERMINATED

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Adv

Interventional Phase III clinical trial protocol NCT04740918 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-07 Enrollment: 96 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04740918
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)96 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04740918
Protocol FieldVerified Registry Value
NCT IdentifierNCT04740918
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment96 participants (ACTUAL)
Registered Start Date2021-06-07
WhyStopped ClassificationInsufficient / Slow Accrual

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI